145 related articles for article (PubMed ID: 31506287)
21. Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation.
Albiero E; Ruggeri M; Fortuna S; Bernardi M; Finotto S; Madeo D; Rodeghiero F
Br J Haematol; 2011 May; 153(3):405-8. PubMed ID: 21275967
[No Abstract] [Full Text] [Related]
22. [Genetic predisposition to pediatric myeloid malignancies].
Muramatsu H
Rinsho Ketsueki; 2016 Jun; 57(6):730-5. PubMed ID: 27384852
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of JAK2 mutations in myeloproliferative disorders.
Knoops L; Hermans C; Ferrant A; Constantinescu SN
Acta Clin Belg; 2008; 63(2):93-8. PubMed ID: 18575049
[TBL] [Abstract][Full Text] [Related]
24. A novel germline
Rajpal S; Jain A; Jamwal M; Jain N; Sachdeva MUS; Malhotra P; Varma N; Das R
Leuk Lymphoma; 2019 Oct; 60(10):2568-2571. PubMed ID: 30990344
[No Abstract] [Full Text] [Related]
25. Makishima H, Saiki R, Nannya Y, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023;141(5):534-549.
Blood; 2024 May; 143(18):1879. PubMed ID: 38696198
[No Abstract] [Full Text] [Related]
26. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
Lauchle JO; Braun BS; Loh ML; Shannon K
Pediatr Blood Cancer; 2006 May; 46(5):579-85. PubMed ID: 16261595
[TBL] [Abstract][Full Text] [Related]
27. JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.
Syeed N
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3611-3615. PubMed ID: 31870101
[TBL] [Abstract][Full Text] [Related]
28. Myeloid neoplasms with germ line RUNX1 mutation.
Hayashi Y; Harada Y; Huang G; Harada H
Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
[TBL] [Abstract][Full Text] [Related]
29. Recurrent Cytogenetic Abnormalities in Myeloproliferative Neoplasms and Chronic Myeloid Leukemia.
Swansbury J
Methods Mol Biol; 2017; 1541():247-256. PubMed ID: 27910028
[TBL] [Abstract][Full Text] [Related]
30. Genomic testing in myeloid malignancy.
Docking TR; Karsan A
Int J Lab Hematol; 2019 May; 41 Suppl 1():117-125. PubMed ID: 31069982
[TBL] [Abstract][Full Text] [Related]
31. [The cutting edge of medicine: pathophysiology and treatment of myeloproliferative neoplasms].
Komatsu N
Nihon Naika Gakkai Zasshi; 2014 Feb; 103(2):440-9. PubMed ID: 24724385
[No Abstract] [Full Text] [Related]
32. Familial predisposition of myeloid malignancies: biological and clinical significance of recurrent germ line mutations.
Matsui H
Int J Hematol; 2017 Aug; 106(2):160-162. PubMed ID: 28631176
[No Abstract] [Full Text] [Related]
33. Genetics of myeloid malignancies: pathogenetic and clinical implications.
Fröhling S; Scholl C; Gilliland DG; Levine RL
J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
[TBL] [Abstract][Full Text] [Related]
34. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
[No Abstract] [Full Text] [Related]
35. Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.
Khan M; Sarfraz M; Daver N
Future Oncol; 2017 Jan; 13(2):117-120. PubMed ID: 27676208
[No Abstract] [Full Text] [Related]
36. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
37. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
Dong B; Zhang Y; Fu X; Wang G
Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
[No Abstract] [Full Text] [Related]
38. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
39. Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm-a comparison of 756 cases.
Baer C; Pohlkamp C; Haferlach C; Kern W; Haferlach T
Leukemia; 2018 Oct; 32(10):2295-2298. PubMed ID: 29725031
[No Abstract] [Full Text] [Related]
40. Fishing the targets of myeloid malignancies in the era of next generation sequencing.
Shi X; He BL; Ma AC; Leung AY
Blood Rev; 2016 Mar; 30(2):119-30. PubMed ID: 26443083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
